electroCore enrolls first patients in gammaCore PTSD study at Acacia Clinics

ELECTROCORE, LLC

ELECTROCORE, LLC

ECOR

0.00
  • electroCore reported first eight patients enrolled in investigator-led clinical study testing gammaCore non-invasive vagus nerve stimulation as add-on treatment for PTSD.
  • Results have not been presented; study will track outcomes over 12-week treatment period, with readout expected in future as trial runs about 10 months.
  • Trial aims to generate early safety and effectiveness evidence to support potential expansion of gammaCore into neuropsychiatric use.
  • Study targets up to 40 adults; Vagus Nerve Society sponsors project, with electroCore supplying devices and an educational grant.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. electroCore Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604070800PRIMZONEFULLFEED9685033) on April 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.